

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/534,348	ATTY. DOCKET NO.: A0848.70005US00
				FILING DATE: May 9, 2005	CONFIRMATION NO.: 1144
				APPLICANT: Silence et al.	
				GROUP ART UNIT: 1649	EXAMINER: Gregory S. Emch
Sheet	1	of	1		

#### U.S. PATENT DOCUMENTS

Examiner's Initials <sup>a</sup>	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials <sup>a</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B23	WO	2004/081026	A	Domantis Limited	09-23-2004	

#### OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials <sup>a</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C19	LORIMER, I.A.J., "Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy," <i>Current Cancer Drug Targets</i> 2002; 2(2):91-102	
	C20	MURUGANANDAM, A. et al., "Selection of phage-displayed llama single-domain antibodies that transmute across human blood-brain barrier endothelium," <i>The FASEB Journal</i> express article. 10.1096/fj.01-0343fje. Published online December 28, 2001; retrieved from <a href="http://www.fasebi.org/cgi/reprint/01-0343fjev1; pp. 1-22">www.fasebi.org/cgi/reprint/01-0343fjev1; pp. 1-22</a>	
	C21	POUL, M. et al., "Selection of Tumor-Specific Internalizing Human Antibodies from Phage Libraries," <i>J. Mol. Biol.</i> 2000; 301:1149-1161	
	C22	WILKSTRAND, C.J. et al., "Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas," <i>Cancer Research</i> 1995 July 15; 55:3140-3148	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

<sup>a</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]